Current and future prospects for the global biotechnology industry

ISSN： 1478-565X

Source： Journal of Commercial Biotechnology, Vol.10, Iss.2, 2003-12, pp. : 154-161

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

The number of biotechnology compounds has been increasing steadily over the past 20 years, reflecting the key contribution that biotechnology is now making to healthcare. Recombinant DNA technology has been used to develop a number of therapeutic proteins, including antibodies, cytokines, hormones and vaccines for use in tackling and diagnosing a range of disorders. Worldwide there are more than 4,000 specialised biotechnology companies. The most well-known companies are located in the USA and Europe, but there are significant companies emerging in Canada, Australia, New Zealand and throughout Asia – particularly in Japan. Most of these companies are small in size and limited when it comes to finances and this has had an impact on the output of the industry in terms of new drugs.Journal of Commercial Biotechnology (2003) 10, 154–161; doi:10.1057/palgrave.jcb.3040069